FAM59B_Fam59b Inhibitors
The chemical class known as FAM59B Inhibitors encompasses compounds that indirectly influence the activity of FAM59B by targeting various components of the MAPK/ERK signaling pathway, as well as other interconnected pathways such as PI3K/Akt and mTOR. These inhibitors are primarily small molecule kinase inhibitors that have the capacity to reduce or alter the activity of key enzymes and receptors involved in the same pathways as FAM59B. Although not interacting with FAM59B directly, their action can modulate the signaling cascade upstream or downstream, thereby impacting the functional effects mediated by FAM59B. For instance, MEK inhibitors like U0126 and PD98059 specifically prevent the activation of MEK1/2, which consequently reduces ERK phosphorylation and its subsequent nuclear translocation, a process in which FAM59B might play a part.
JNK and p38 MAP kinase inhibitors such as SP600125 and SB203580, respectively, target other branches of the MAPK signaling network, offering another route to alter the signaling milieu in which FAM59B operates. The PI3K/Akt pathway inhibitors, LY294002 and Wortmannin, demonstrate the interconnected nature of intracellular signaling by affecting pathways that are not exclusively MAPK but are linked to it, thus exerting an indirect regulatory effect on FAM59B's role. Additionally, compounds like Rapamycin target the mTOR pathway, which is another significant regulator of cell growth and survival, with potential links to the MAPK pathway. Inhibition of receptor tyrosine kinases by chemicals such as Sunitinib, Sorafenib, Erlotinib, and Gefitinib showcases a broader strategy, as these kinases are often the initiating factors of signaling cascades that include MAPK. Lastly, Trametinib represents a specific MEK inhibitor that further exemplifies the targeted approach within this chemical class to modulate the MAPK pathway, consequently influencing the biological context of FAM59B activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK, a kinase upstream of MAPK in the signaling cascade. By inhibiting MEK, U0126 prevents the activation of MAPK/ERK, which can impact the regulatory effects FAM59B exerts on the MAPK pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is another MEK inhibitor that acts by binding to the inactive form of MEK, thereby preventing its activation. This action results in reduced MAPK/ERK signaling, potentially altering the functional influence of FAM59B within this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of another MAPK pathway. JNK inhibition can modulate the cellular processes that FAM59B may affect indirectly, as JNK activity is relevant to various stress responses and apoptotic signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase, another key player in MAPK signaling. The inhibition of p38 kinase can affect the regulatory roles of FAM59B indirectly through the modulation of this specific MAPK pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that blocks the PI3K/Akt pathway, which is known to cross-talk with MAPK signaling pathways. Through this inhibition, the activity of FAM59B within the interconnected network of signaling pathways might be indirectly influenced. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor with a mechanism of action similar to LY294002. By inhibiting PI3K, it can affect the regulatory roles that FAM59B has on signaling pathways that interact with or are parallel to the PI3K/Akt pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which is part of the mTOR signaling pathway that also interacts with MAPK signaling. The inhibition of mTOR can lead to changes in the regulation of downstream targets and processes that FAM59B may be involved in. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor that can inhibit growth factor signaling, leading to reduced MAPK pathway activation. This reduction can alter the influence of FAM59B on the signaling pathway, as growth factor signaling is upstream of MAPK/ERK activation. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that targets RAF kinases among others, which are upstream of MEK and ERK in the MAPK pathway. By inhibiting RAF, Sorafenib can impact the regulatory role of FAM59B within this signaling cascade. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an EGFR inhibitor that can reduce the activation of the MAPK pathway by inhibiting the initial growth factor receptor signaling. This can indirectly alter the functional effects of FAM59B on MAPK pathway-related processes. | ||||||